Suppr超能文献

患者对慢性肾脏病和肾衰竭中使用大麻的看法:一项调查研究。

Patient views regarding cannabis use in chronic kidney disease and kidney failure: a survey study.

机构信息

Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

出版信息

Nephrol Dial Transplant. 2023 Mar 31;38(4):922-931. doi: 10.1093/ndt/gfac226.

Abstract

BACKGROUND

Cannabis is frequently used recreationally and medicinally, including for symptom management in patients with kidney disease.

METHODS

We elicited the views of Canadian adults with kidney disease regarding their cannabis use. Participants were asked whether they would try cannabis for anxiety, depression, restless legs, itchiness, fatigue, chronic pain, decreased appetite, nausea/vomiting, sleep, cramps and other symptoms. The degree to which respondents considered cannabis for each symptom was assessed with a modified Likert scale ranging from 1 to 5 (1, definitely would not; 5, definitely would). Multilevel multivariable linear regression was used to identify respondent characteristics associated with considering cannabis for symptom control.

RESULTS

Of 320 respondents, 290 (90.6%) were from in-person recruitment (27.3% response rate) and 30 (9.4%) responses were from online recruitment. A total of 160/320 respondents (50.2%) had previously used cannabis, including smoking [140 (87.5%)], oils [69 (43.1%)] and edibles [92 (57.5%)]. The most common reasons for previous cannabis use were recreation [84/160 (52.5%)], pain alleviation [63/160 (39.4%)] and sleep enhancement [56/160 (35.0%)]. Only 33.8% of previous cannabis users thought their physicians were aware of their cannabis use. More than 50% of respondents probably would or definitely would try cannabis for symptom control for all 10 symptoms. Characteristics independently associated with interest in trying cannabis for symptom control included symptom type (pain, sleep, restless legs), online respondent {β = 0.7 [95% confidence interval (CI) 0.1-1.4]} and previous cannabis use [β = 1.2 (95% CI 0.9-1.5)].

CONCLUSIONS

Many patients with kidney disease use cannabis and there is interest in trying cannabis for symptom control.

摘要

背景

大麻被广泛用于娱乐和医疗用途,包括用于肾病患者的症状管理。

方法

我们征求了加拿大肾病患者对大麻使用的看法。参与者被问及他们是否会尝试使用大麻来缓解焦虑、抑郁、不安腿、瘙痒、疲劳、慢性疼痛、食欲下降、恶心/呕吐、睡眠、痉挛和其他症状。通过使用改良的 Likert 量表(范围从 1 到 5,1 表示肯定不会,5 表示肯定会)来评估受访者对每种症状考虑大麻的程度。多水平多变量线性回归用于确定与考虑大麻控制症状相关的受访者特征。

结果

在 320 名受访者中,290 名(90.6%)来自面对面招募(27.3%的回应率),30 名(9.4%)来自在线招募。共有 160/320 名受访者(50.2%)之前使用过大麻,包括吸烟[140(87.5%)]、油[69(43.1%)]和食用品[92(57.5%)]。以前使用大麻的最常见原因是娱乐[84/160(52.5%)]、缓解疼痛[63/160(39.4%)]和改善睡眠[56/160(35.0%)]。只有 33.8%的以前使用过大麻的患者认为他们的医生知道他们使用大麻。超过 50%的受访者可能会或肯定会尝试使用大麻来控制所有 10 种症状。与尝试使用大麻控制症状相关的独立特征包括症状类型(疼痛、睡眠、不安腿)、在线受访者[β=0.7(95%置信区间(CI)0.1-1.4)]和以前使用大麻[β=1.2(95% CI 0.9-1.5)]。

结论

许多肾病患者使用大麻,并且有兴趣尝试使用大麻控制症状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验